Search results for: Oncology
Filter search results
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
1 June 2018
Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such as immunotherapies….
The Expanding Value Footprint of Oncology Treatments
1 May 2014
The cohort of cancer drugs included are the ten approved by the EMA during 2003–2005. This time period was chosen based on the assumption that cancer drugs on the market…
Assessment and Appraisal of Oncology Medicines: NICE’s Approach and International HTA Experience
1 February 2009
Lower usage of cancer medicines in the UK compared to other countries has created questions, including whether the current approach by NICE to assessing cancer medicines is an important factor…
New OHE Research Paper: Extrapolation from Progression Free Survival to Overall Survival in Oncology
28 December 2016
…Oncology. The Office of Health Economics, in a research project funded by the Pharmaceutical Oncology Initiative (POI), has published a new report entitled: Extrapolation from Progression Free Survival to Overall…
Progression-free Survival as a Surrogate Outcome for Overall Survival in Oncology
4 September 2018
When should progression-free survival be used as a surrogate for overall survival in oncology? A recent article in the International Journal of Technology Assessment in Health Care, co-authored by OHE…
Extrapolation from Progression-Free Survival to Overall Survival in Oncology
1 December 2016
This Research Paper reports on a literature review of trials using PFS as a surrogate for OS in oncology between 2012 and 2016; a workshop and interviews involving people from…
Advances in Oncology Modelling: Recent Results from POI Research
18 September 2012
OHE and the Pharmaceutical Oncology Initiative (POI) held a workshop to discuss and debate several key issues in oncology modelling. Participating were more than 50 experts from industry, academia and…
Spotlight on OHE: Value Footprint of Oncology Treatments, Treating Obstructive Sleep Apnoea and Sources of Motivation in Health Care Organisations
4 August 2015
The blog provides links to slide sets and posters relating to the value footprint of oncology treatments, treating obstructive sleep apnoea and sources of motivation in health care organisations. Speaking…
Innovation in Oncology: Real Option Value and Path Dependence
29 April 2014
Real Option Value and Path Dependence in Oncology Innovation. Based on an OHE Lunchtime Seminar, this Seminar Briefing addresses a persistent issue: how to adequately reward innovation through the pricing…